Immunophotonics is a privately owned clinical stage biotech that has discovered a novel and simple approach to achieve patient-specific anticancer immunity. The company is currently developing its first asset, the immune-modulating proprietary carbohydrate polymer IP-001 for the treatment of solid tumor cancers. IP-001 has unique physio-chemical and immunological properties that allows it to ignite a systemically active cancer immunotherapy from a routine tumor ablation; a minimal invasive intervention that destroys tumors and in doing so liberates tumor antigens. IP-001 enhances interactions of tumor antigens with the immune system, improves the motility of tumor infiltrating T cells, promotes their surveillance of tumor tissue and can generate long-term protective immunity.
Company Details
- Employees
- 19
- Founded
- 2012
- Address
- Biogenerator Labs, Suite 212, 4340 Duncan Ave.,switzerland
- Phone
- 636-675-6161
- Industry
- Pharmaceutical Manufacturing
- NAICS
-
Pharmaceutical and Medicine ManufacturingMedicinal and Botanical ManufacturingPharmaceutical Preparation ManufacturingIn-Vitro Diagnostic Substance ManufacturingBiological Product (except Diagnostic) Manufacturing
- Website
- immunophotonics.com
- Keywords
- Biotech, Cancer, Immunotherapy, Ablation.
- HQ
- St. Louis, Missouri
Immunophotonics, Inc. Questions
Immunophotonics, Inc.'s helpline number is 636-675-6161
Immunophotonics, Inc.'s website is immunophotonics.com
Immunophotonics, Inc.'s LinkedIn profile is https://www.linkedin.com/company/immunophotonics-inc
Immunophotonics, Inc. has
19 employees.
View email and phone details for 19
employees at Immunophotonics, Inc..
Immunophotonics, Inc.'s industry is
Pharmaceutical Manufacturing
Immunophotonics, Inc.'s top competitors are
Boondoggle Ai,
The Animal Neurology Center,
Timebolt.io,
Capacity,
Cortex Innovation District,
Muia Materials,
Kwema,
Startup World Cup,
Techstl,
King Of The Curve (Kotc).
Immunophotonics, Inc.'s categories are Pharmaceutical Manufacturing
Immunophotonics, Inc.'s founding year is 2012
